

DAFTAR PUSTAKA

- Abad, C.L., Kumar, A., Safdar, N., 2011. Antimicrobial Therapy of Sepsis and Septic Shock—When Are Two Drugs Better Than One?. **Crit Care Clin.** Vol. 27, pp. e1–e 27.
- Amanullah, S. and Venkataraman, R., 2004. The Routine Use of Albumin for Fluid Resuscitation of Critically Ill Patients is Not Warranted. **Crit Care Med.** Vol. 8 No. 6.
- Angus, D.C., Linde–Zwirble, W.T., Lidicker, J., Clermont, G., Carcillo, J., Pinsky, M.R., 2001. Epidemiology of Severe Sepsis in The United States: Analysis of Incidence, Outcome, and Associated Costs of Care. **Crit Care Med.** Vol. 29, pp. 1303 – 1310.
- Balk, R.A., 2000. Pathogenesis and management of multiple organ dysfunction or failure in severe sepsis and septic shock. **Crit Care Clin.** Vol. 16 No. 2, pp. 337 – 352.
- Balk, R.A., 2004. Optimum Treatment of Severe Sepsis and Septic Shock: Evidence In Support of the Recommendation. **Dis Mon.** Vol. 50, pp. 168–213.
- Biffl, W. L., Moore, E. E., Moore, F. A., 2002. The two-hit Model of MODS. *In*: Deitch, E. A., Vincent, J. L., Winder A. And W. B. Saunders (Eds.). **Sepsis and Mutiple Organ Dysfunction.** London: J. B. Lippincott Co., pp. 127-135.
- Birken, S., Lena, K., Dipiro, J.T., 2008. Sepsis and Septic Shock. *In*: Joseph T. Dipiro. **Pharmacotherapy A Pathophysiology Approach**, Ed. 7th, New York: The McGraw-Hill Companies, Inc., pp. 1943 – 1955.
- Bloch, K. C., 2014. Infectious Diseases. *In*: Mc Phee, S.J. and Gary D. H. (Eds.). **Pathophysiology of Disease: An Introduction to Clinical Medicine**, Ed. 7th. USA: The Mc Graw-Hill Companies, pp. 82 -86.
- Boldt, J., 2010. Use of Albumin : an Update. **BJA.** pp. 276 – 285.

- Charney, D. S., Mihic, S. J., Harris, R. A., 2001. Hipnotik dan Sedatif. Dalam: Goodman & Gilman. **Dasar Farmakologi Terapi**. Diterjemahkan oleh Tim Alih Bahasa Sekolah Farmasi ITB. Jakarta: Penerbit Buku Kedokteran EGC. pp. 386-415.
- Chen, K., dan Widodo, D., 2004. Patofisiologi Sepsis: Peran Mediator Inflamasi. *Dalam*: Djoko Widodo, Herdiman T. Pohan (Eds.). **Bunga Rampai Penyakit Infeksi**, Edisi Pertama. Jakarta: Pusat Penerbitan Departemen Ilmu Penyakit Dalam. Hal. 54-61.
- Chou, C. D., Yien, H. W., Wu, D. M., Kuo, C. D., 2009. Albumin Administration in Patients with Severe Sepsis due to Secondary Peritonitis. **J Chin Med Assoc**. Vol. 72, pp. 243-250.
- Cipolle, R.J., Strand, L.M., Morley, P.C. 2007. **Pharmaceutical Care Practice: The Clinicians Guide**, Ed. 2nd Vol. 9, New York: McGraw-Hill.
- Committee for Medicinal Products for Human Use, 2012. Guideline on core SmPC for human albumin solution. **EMA**.
- Daley, B. J., 2015. Peritonitis and Abdominal Sepsis. **Emedicine**, diakses dari <http://emedicine.medscape.com/article/180234-overview> pada tanggal 22 Juli 2015.
- Daniels, R., 2010. Identifying the Patient with Sepsis. *In*: Ron Daniels and Nutbeam (Eds.). **ABC of Sepsis**. BMJ Publishing Group Limited. pp. 10-14.
- Davis, F. A., 2005. **IV Therapy Notes, Nurse Clinical Pocket Guide**. Philadelphia: F. A. Davis Company Philadelphia. p. 26, 135, 138.
- Dellinger, R.P., Levy, M.M., Rhodes, A., Annane, D., Gerlach, H., Opal, S.M., Sevransky, J.E., Sprung, C.L., Douglas, I.S., Jaeschke, R., Osborn, T.M., Nunnally, M.E., Townsend, S.R., Konrad, R., Kleinpell, R.M., Angus, D.C., Vincent, J.L., Moreno, R., 2012. **Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock**. Diakses dari www.survivingsepsis.org, pada tanggal 9 Januari 2015.

- Depkes RI, 1995. **Farmakope Indonesia**, Ed.4. Jakarta: Departemen Kesehatan.
- Dwijayanti, D. R., Djati, M. S., Ibrahim, M., Rifa'i, M., 2015. The Potential of VipAlbumin to Chronic Inflammation in Type 2 Diabetes Mellitus Balb/C Mice Model. **Americ J Immun.**
- Franch-Arcas, G., 2001. The Meaning of Hypoalbuminemia in Clinical Practice. **Clin Nutri.** Vol. 20, pp. 265-269.
- Gatta, A., Verardo, A., Bolognesi, M., 2012. Hypoalbuminemia. **Intern Emerg Med.** Vol. 7, pp. S193 – S199.
- Girard, T. D., and Ely, E. W., 2006. Delirium in Septic Patients: An Unrecognized Vital Organ Dysfunction. *In: Guillermo Ortiz-Ruiz, Marco A. Perafan, Eugen Faist, and Carmelo Duenas Castell (Eds.). Sepsis*, Ed. 2nd, United States of America: Springer Sciences Business Media, Inc., pp. 150-156.
- Greenhalgh, D.G., Saffle, J.R., Holmes, J.H., Gamelli, R.L., Palmieri, T.L., Horton, J.W., Tompkins, R.G., Traber, D.L., Mazingo, D.W., Deitch, E.A., Oodwin, C.W., Herndon, D.N., Gallagher, J.J., Sanford, A.P., Jeng, J.C., Ahrenholz, D.H., Neely, A.N., O'Mara, M.S., Wolf, S.E., Purdue, G.F., Garner, W.L., Yowler, C.J., Latenser, B.A., 2007. American Burn Association Consensus Conference to Define Sepsis and Infection in Burns. **J Burn Care Res.** Vol. 28 No. 6, pp. 776 – 790.
- Guidet, B., Mosqueda, G.J., Priol, G., Aegerter, P., 2007. The COASST Study: Cost-Effectiveness of Albumin in Severe Sepsis and Septic Shock. **J Crit Care.** Vol. 22, pp. 197 – 203.
- Hahn, G. R., 2011. Colloid Fluids. *In: Critical Fluid Therapy in The Perioperative Setting*. New York: Cambridge University Press.
- Guntur, A. H., 2006. Sepsis. Dalam: Sudoyo Aru W., **Buku Ajar Ilmu Penyakit Dalam**, Jilid III Edisi IV. Jakarta: Pusat Penerbitan Departemen Ilmu Penyakit Dalam. Hal. 1862-1865.

- Harbarth, S., Garbino, J., Pugin, J., 2003. Inappropriate Initial Therapy and It's Effect on Survival in a Clinical Trial of Immunomodulating Therapy for Severe Sepsis. **Am. J. Med.**, Vol. 115, pp. 529-535.
- Hermawan, A. G., 2007. Kunci Tatalaksana Sepsis. **Gerai**, Edisi Februari 2007. Vol. 6, No. 7, pp. 35-50.
- Hollenberg, S.M., Ahrens, T.S., Annane, D., Astiz, M.E., Chalfin, D.B., Dasta, J.F., Heard, S.O., Martin, C., Napolitano, L.M., Susla, G.M., Totaro, R., Vincent, J.L., Cavazzoni, S.Z., 2004. Practice Parameter for Hemodynamic Support of Sepsis Patients: 2004 Update. **Crit Care Med**, Vol. 32 No. 9, pp. 1928 – 2008.
- Holloway, K. and Terry, G., 2003. **Drug and Therapeutics Committees a Practical Guide**. WHO, pp. 85 - 90.
- Hwang, T. L., 2009. Potential Use of Albumin Administration in Severe Sepsis. **J Chin Med Assoc**. Vol. 72, No. 5, pp. 225-256.
- Jahangard-Rafsanjani, Z., Javadi, M. R., Torkamandi, H., 2011. The Evaluation of Albumin Utilization in a Teaching University Hospital in Iran. **Iran J Pharm Res**. Vol. 10. pp. 385-390.
- Joenoës, N. Z., 2012, **Ars Prescribendi-Resep yang Rasional Jilid 3**. Surabaya: Airlangga University Press, pp. 135-158.
- Johnson, M., Parra, A., Garcia, R., Barthol, C., 2010, **Guideline for Use Albumin**. Diakses dari <https://www.universityhealthsystem.com> pada 7 September 2014.
- Join Formulary Committee, 2014. **British National Formulary**. 67 penyunt. London: Pharmaceutical Press.
- Landenberg, P.V dan Shoenfeld, Y., 2001. New approach in the diagnosis of sepsis. **IMAJ**. Vol. 3, pp. 439 – 442.
- Levy, M. M., 2010. Introduction. *In*: Ron Daniels and Tim Nutbeam. **ABC of Sepsis**. pp. 1-4.

- Liumbruno, G. Bennardello, F., Lattanzio, A., Piccoli, P., Rosetti, G., 2009. Recommendations for the Use of Albumin and Immunoglobulins. **Blood Transf.** Vol. 7, pp. 216-234.
- Martin, G.S., Mannino, D.M., Eaton, S., Moss, M., 2003. The Epidemiology of Sepsis in The United States from 1979 through 2000. **N Engl J Med.** Vol. 348, pp. 1546 – 1554.
- McNamara, J. O., 2001. Obat-obat yang Efektif Dalam Terapi Epilepsi. Dalam: Goodman & Gilman. **Dasar Farmakologi Terapi.** Diterjemahkan oleh Tim Alih Bahasa Sekolah Farmasi ITB. Jakarta: Penerbit Buku Kedokteran EGC. pp. 506-532.
- Mc Evoy, G.K., 2011. **AHFS Drug Information Essentials.** Bethesda: American Society of Health-System Pharmacists.
- Mc Graw Hill. 2005. **Concise Encyclopedia of Science and Technology**, Ed. 5th. New York: Mc Graw Hill, p. 68.
- Mc Graw Hill. 2007. **Encyclopedia of Science and Technology**, Ed. 10th Vol. 1. New York: Mc Graw Hill, pp. 409 – 410.
- Moenedjat. 2009. **Luka Bakar Masalah dan Tatalaksana.** Jakarta: Balai Penerbit FKUI.
- Munford, R.S., 2005., Enteral and Parenteral Nutrition Therapy. *In*: J. Larry Jameson, E. Braunwald, K. J. Isselbacher, R. G. Petersdorf, J. D. Wilson, J. B. Martin, A. S. Fauci, R. Root, D. L. Kasper, S. L. Hauser, and D. L. Longo (Eds.). **Harrison's Manual of Medicine**, Ed. 16th, United States of America: The McGraw-Hill Companies, Inc., pp. 49-53.
- Mustafa, A., Widodo, M. A., Kristianto, Y., 2012. Albumin and Zinc of Snakehead Fish (*Channa striata*) Extract and Its Role in Health. **IJSTE.** Vol. 1, pp. 1-8.
- Nasronudin, 2006. Sepsis in Immunocompromised Patients: Principles of Prevention and Management. *Dalam*: S. Adi, Nasronudin, A. Sutahjo, A. Tjokropawiro, J. Soeroso, A. Panoto, dan C.

Irwanadi (Eds.). **Naskah Lengkap Pendidikan Kedokteran Berkelanjutan XXI Ilmu Penyakit Dalam**. Surabaya: Bagian SMF Penyakit Dalam Fakultas Kedokteran Universitas Airlangga, hal. 132-47.

National Plasma Product Expert Advisory Group. 2009. **Clinical Guidelines for Human Albumin Use**. NHS Scotland.

NCQA, 2014. **Health Plan Accreditation Requirements**. Diakses dari ncqa.org pada 26 Januari 2015.

Neviere, R., 2007. Sepsis and the Systemic Inflammatory Response Syndrome: Definitions, Epidemiology, and Prognosis. **Society of General Internal Medicine**, Version 15.3

Nutbeam, Tim., 2010. Initial Resuscitation. *In*: Daniels, Ron. dan Nutbeam, Tim (eds.). **ABC of Sepsis**. Chennai: Blackwell Publishing, pp. 20 – 36.

Ontario Regional Blood Coordinating Network. 2015. **Ontario Albumin Administration Recommendations**. ORBCON.

Opal, S. M., and Huber, C. E., 2003. Sepsis. *In*: Dale, D. C., **Infectious Disease, Clinician's Guide to Current Diagnosis, Treatment, and Prevention**, Ed. 1st. Washington: WebMD Professional Publishing, pp. 33-42.

Otero, R.M., Nguyen, H.B., Huang, D.T., Galeski, D.F., Goyal M., Gunnerson, K.J., 2006. Early Goal Directed Therapy in Severe Sepsis and Septic Shock Revisited: Concepts, Controversies, and Contemporary Findings. **Chest**. Vol. 130 No. 5, pp. 1579 – 1595.

Menteri Kesehatan RI. 2014. **Peraturan Menteri Kesehatan RI Nomor 28 Tahun 2014 Tentang Pedoman Pelaksanaan Program Jaminan Kesehatan Nasional**. Menteri Kesehatan RI.

Menteri Kesehatan RI. 2014. **Keputusan Menteri Kesehatan RI Nomor 159/Menkes/SK/V/2014 Tentang Perubahan Atas Keputusan Menteri Kesehatan Nomor**

328/Menkes/SK/IX/2013 Tentang Formularium Nasional.
Menteri Kesehatan RI.

- Rivers, E.P., Katranji, M., Jaehne, K.A., Brown, S., Dagher, G.A., Cannon, C. Coba, V., 2012. Early Interventions in severe sepsis and septic shock: a review of the evidence one decade later. **Minerva Anesthesiologica**. Vol. 78 No. 6, pp. 712 – 724.
- RSUD Dr. Soetomo. 2003. **Pedoman Penggunaan Albumin Edisi 3**. RSUD Dr. Soetomo.
- Shargel, L., Wu-Pong, S. & Yu, A.B., 2004. **Applied Biopharmaceutics and Pharmacokinetics**. New York: McGraw Hill.
- Sharma, S., 2014: Multiple Organ Dysfunction Syndrome in Sepsis. **Emedicine**, diakses dari <http://emedicine.medscape.com/article/169640-overview#a0101> pada tanggal 12 Januari 2015.
- Soegijanto, S. dan Huda, N. 2010. **Kumpulan Makalah Penyakit Tropis dan Infeksi di Indonesia**. Surabaya: Airlangga University Press, pp. 350 – 366.
- Somers, A., Bauters, T., Robays, H., Bogaert, M., Colardyn, F., 2002. Evaluation of Human Albumin Use in a University Hospital in Belgium. **Pharm World Sci**. Vol. 24, pp. 111-116.
- Soni, N., 2009. Human Albumin Solutions and the Controversy of Crystalloids Versus Colloid. *In*: M. Contreras, penyunt. **ABC of Transfusions**. West Sussex: Wiley Blackwell, pp. 48-53.
- Soni, N., 2014. Wonderful Albumin. **BMJ**. Vol. 310, p. 887.
- Suharto. 2005. Current Therapy of Severe Infection. *Dalam*: S. Adi, Nasonudin, A. Sutahjo, A. Tjokroprawiro, J. Soeroso, A. Pranoto, dan C. Irwanadi (Eds.). **Naskah Lengkap Pendidikan Kedokteran Berkelanjutan XX Ilmu Penyakit Dalam**. Surabaya: Bagian SMF Penyakit Dalam Fakultas Kedokteran Universitas Airlangga. Hal. 199-211.

- Sundararajan, V., MacIsaac, C. M., Presnill, J. J., Cade, J. F., and Visvanathan, K., 2005. Epidemiology of Sepsis in Victoria, Australia. **Crit Care Med.** Vol. 33, No. 1, pp. 71-80.
- Sutton, S.S., 2008. Sepsis and Septic Shock. *In*: Joseph T. Dipiro. **Pharmacotherapy Principles & Practice**, New York: The McGraw-Hill Companies, Inc., pp. 1185 – 1198.
- U.S. Department of Health & Human Services. 2008. **Centers for Medicare & Medicaid Services**. Diakses dari <http://www.amcp.org/> pada tanggal 25 Januari 2015.
- U.S. Department of Health & Human Services. 2009. **Common Terminology Criteria for Adverse Events (CTCAE)**. Diakses dari <http://evs.nci.nih.gov> pada tanggal 5 Februari 2015.
- Vincent, J. L., Sakr, Y., Sprung, C. L., Ranieri, M., Reinhart, K., Gerlach, H., Moreno, R., Carlet, J., Le-Gall, J. R., Payen, D., 2006. Sepsis in European Intensive Care Units: Results of the SOAP Study. **Crit Care Med.** Vol. 34, No. 2, pp. 344-353.
- Ward NS, Casserly B, Ayala A., 2008. The compensatory anti-inflammatory response syndrome (CARS) in critically ill patients. **Clin Chest Med.** Vol. 29, pp. 617-625 viii.
- Widodo, AD. dan Tumbelaka, AR., 2010. Penggunaan Steroid dalam Tata Laksana Sepsis Analisis Kasus Berbasis Bukti. **Sari Pedriatri.** Vol. 11, No. 6, pp. 387 – 394.
- Yamasaki, K., Chuang, V.T.G., Maruyama, T., Otagiri, M., 2013. Albumin – drug interction and its clinical implication. **BBA.** pp. 5435 – 5443.